Woulgan® Biogel market update

Biotec BetaGlucans has so far distributed test samples to 14 different health institutions in Norway, and receives very positive product feedback.

All in all, we have distributed close to 10,000 tubes of Woulgan® Biogel since the product received its CE-mark in April, says CEO Svein Lien.

The planned market evaluation study together with Smith & Nephew is continuing - centre recruitment is early with centres in Germany and UK recruited but too soon to report outcomes. The intention of the market evaluation study is to gain experience from health care professionals and get their view of Woulgan® Biogel’s end-user efficacy in a routine clinical setting.

A survey of Norwegian health care professionals and opinion leaders testing of Woulgan® Biogel is being conducted with feedback starting to come in.

-In Norway, the reports we have received so far are all positive, and several health institutions wish to continue testing. We have also shipped product samples to approximately 100 other health care professionals and are working to recruit some of these into more formal tests to make sure we receive broad feedback on how health care personnel experience Woulgan® Biogel in practical use, says Lien.

Woulgan® Biogel combines hydrogel components with the company’s proprietary soluble beta glucan SBG, and has been CE-marked as an advanced medical device Class III, Rule 13 under the EU Directive for Medical Devices. Woulgan® Biogel has been shown to have positive effects on the body’s own wound healing capabilities, and offers a new treatment alternative to large patient groups looking for improved solutions for healing of chronic.

Woulgan® Biogel is a single-use primary dressing for treatment of skin wounds. Biotec BetaGlucans will initially address diabetic ulcers, leg ulcers, pressure ulcers, and burns, although the product is also approved for use on other wounds like post-surgery wounds, trauma wounds, and abrasions.

Woulgan® Biogel is available from Biotec BetaGlucan’s web-shop; www.biotec.no.

For further information, please contact:

CEO Svein W. F. Lien, tel +47 922 89 323
CSO Rolf E. Engstad, tel +47 959 41 542

About Biotec BetaGlucans and Woulgan® Biogel

Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec BetaGlucans develop and manufactures novel immunomodulating products. Newly developed Woulgan® Biogel for use in wound healing, contains the company’s proprietary substance SBG®. Woulgan® Biogel is a sterile, homogen, thick gel containing water, glycerol, 2% SBG, and carboxymethylcellulose. The product does not contain any preservatives. The Woulgan® Biogel is a single-patient primary dressing for one-time use on skin wounds including diabetic ulcers, bedsores, leg ulcers, transplantation wounds, post-surgery wounds, trauma wounds, first- and second-degree burns, abrasions, and cuts. The company has entered into an agreement with world leaders Smith & Nephew for distribution of Woulgan® Biogel after a market evaluation period based on regular clinical use.

More information about Woulgan® Biogel is available on the company’s homepage www.biotec.no